In the first four months of 2026, Russians purchased over 17.6 million minimum dosage units (MDU) of veterinary anthelmintic drugs (groups P52A and P54A*) in specialized pharmacies and pet stores. Compared to the same period last year, physical demand for such products increased by 11.2%. In monetary terms, the segment's volume reached RUB 3.3 billion (at retail prices, including VAT), exceeding the January–April 2025 figure by 15.1%. These figures confirm a sustained multi-year trend of market expansion. In 2025, the total sales volume of animal deworming products amounted to 49.5 million physical units worth RUB 9.3 billion. Compared to 2022, physical sales volumes grew by more than 37%, while ruble revenue in the category increased by 85%.

Moreover, the popularity of domestic veterinary anthelmintic drugs is steadily growing. According to the "Retail Audit of Veterinary Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, in January–April 2026, their share in physical terms reached 78%. However, the monetary volume of Russian products is not as high, accounting for 43% of the market during this period. Compared to January–April 2025, sales of Russian companies increased by 11.2% in MDU and 17.1% in monetary terms. Meanwhile, demand for imported products showed comparable dynamics of 11.2% in MDU and 13.7% in rubles. However, during the reporting period, there was a reduction in supplies from some key foreign companies from countries such as Germany (-63% in MDU), France (-84%), and Latvia (-92%).

Against the backdrop of some key foreign players exiting the market, Slovenia has secured a leading position, with its ruble share reaching 32.6% and continuing to grow steadily. The opposite dynamic is observed for U.S. products, whose presence has been steadily declining in recent years: in January–April of this year, the share of U.S. suppliers fell to 23.5% in rubles, whereas last year they controlled about 33% of all retail spending in the category. At the same time, there is an expansion of Belarusian manufacturers, with the combined portfolio of these companies in the analyzed group expanding to 28 product names. This allowed Belarus to surpass Germany in supply volumes and capture 0.5% of the total monetary value of the Russian retail market for animal anthelmintic drugs.

In January–April 2026, the veterinary anthelmintic market featured a total of 144 trademarks from 19 Russian and 31 foreign companies. The leader in the segment in monetary terms remained the brand Milprazon (INN milbemycin oxime + praziquantel) from Slovenian KRKA, with a 16% share and annual revenue growth of 20.3%. Second place was held by the American Milbemax (INN milbemycin oxime + praziquantel) from Elanco, accounting for 15.2% of the market with sales growth of 11.3%. Among the top products, the highest growth rate during the reporting period was shown by the Russian brand Dirofen from Apicenna, which climbed to 10th place in the ranking thanks to a growth rate of +75.2% in rubles.

Fig. Structure of the Russian Retail Market for Veterinary Anthelmintic Drugs by Country of Origin (including online channel)

*This review analyzes the following groups of veterinary drugs according to the WHO classification: P52A — Anthelmintics and P54A — Macrocyclic lactones. A number of drugs in group P54A are used both as anthelmintics and as drugs for the treatment of ectoparasites; however, in the vast majority of cases, the anthelmintic properties of the drugs are the primary indication for use.